Osiris Therapeutics Announces Cardiac Stem Cell Therapy Presentation At BMT Tandem Meeting
Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced that data from a 53-patient double-blind, placebo controlled trial studying the treatment of heart attack patients with Prochymal, a proprietary formulation of mesenchymal stem cells (MSCs), as well as research on the underlying mechanism of action of MSCs for cardiac repair, will be presented at the 2010 BMT Tandem Meeting. Joshua M. Hare, M.D…
Related News:
Osiris Therapeutics Announces Cardiac Stem Cell Therapy Presentation …
Osiris Therapeutics Provides Update on Groundbreaking Stem Cell Trial for Type 1 Diabetes
Osiris Reports Positive Two-Year Data on Stem Cell Treatment for Acute Myocardial Infarction (Centre Daily Times)